Ross is ferocious on this point. In interviews and grand rounds, she repeatedly notes that up to 20% of lung cancer deaths occur in never-smokers. She points out the rise of EGFR and ALK mutations in young, non-smoking women—a cohort that is mysteriously increasing.
Early data suggests this can cut the risk of recurrence in half for certain patients. In an era of "influencers" and viral health trends, Dr. Jarushka Ross represents the opposite: the quiet, rigorous, data-driven clinician who sits with a terrified family at 6 PM on a Friday. jarushka ross
While pharmaceutical reps were handing out brochures about the "power of immunotherapy," Ross was publishing landmark papers in The New England Journal of Medicine and The Lancet Oncology detailing the "when" and "how" of these toxicities. She created the first algorithms for community oncologists to manage a patient who develops sudden diabetes or a heart arrhythmia from a checkpoint inhibitor. “We can’t just turn off the immune system without turning off the fight against the cancer,” she has argued. “It’s a balance. We need to be smarter than the biology.” One of the most striking things about Ross is her refusal to let patients carry the burden of guilt. Lung cancer carries a unique shame that breast or colon cancer does not: the assumption that the patient "did it to themselves" via smoking. Ross is ferocious on this point
She isn’t looking for a cure-all magic bullet. She is looking for control . She wants to turn lung cancer from a death sentence into a chronic illness—like diabetes or high blood pressure. Something you manage, not something you die from. Early data suggests this can cut the risk
Landing at the , Ross found herself at ground zero of the immunotherapy revolution. This wasn’t just chemotherapy anymore; this was teaching the body’s own immune system to see a tumor as an invader. But there was a dark side to this miracle.